arrow
Return

Recapitulating thyroid cancer histotypes through engineering embryonic stem cells

delete2023-03-11
delete12
delete
OA
AI
V
Veronica Veschi
A
Alice Turdo
C
Chiara Modica
F
Francesco Verona
S
Simone Di Franco
M
Miriam Gaggianesi
E
Elena Tirrò
S
Sebastiano Di Bella
M
Melania Lo Iacono
V
Vincenzo Davide Pantina
P
Porcelli, Gaetana
L
Laura Rosa Mangiapane
P
Paola Bianca
A
Aroldo Rizzo
E
Elisabetta Sciacca
I
Irene Pillitteri
V
Veronica Vella
A
Antonino Belfiore
M
Maria Rita Bongiorno
G
Giuseppe Pistone
L
Lorenzo Memeo
L
Lorenzo Colarossi
D
Dario Giuffrida
C
Cristina Colarossi
P
Paolo Vigneri
M
Matilde Todaro
G
Giorgio Stassi *
DOI:10.1038/s41467-023-36922-1delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Thyroid carcinoma (TC) is the most common malignancy of endocrine organs. Here, the authors show the ability of human embryonic stem cells (hESCs) to recapitulate the different TC histotypes upon specific genomic alterations delivered by CRISPR-Cas9 and identify KISS1R and TIMP1 targeting as a therapeutic adjuvant option for undifferentiated TCs. Thyroid carcinoma (TC) is the most common malignancy of endocrine organs. The cell subpopulation in the lineage hierarchy that serves as cell of origin for the different TC histotypes is unknown. Human embryonic stem cells (hESCs) with appropriate in vitro stimulation undergo sequential differentiation into thyroid progenitor cells (TPCs-day 22), which maturate into thyrocytes (day 30). Here, we create follicular cell-derived TCs of all the different histotypes based on specific genomic alterations delivered by CRISPR-Cas9 in hESC-derived TPCs. Specifically, TPCs harboring BRAF(V600E) or NRAS(Q61R) mutations generate papillary or follicular TC, respectively, whereas addition of TP53(R248Q) generate undifferentiated TCs. Of note, TCs arise by engineering TPCs, whereas mature thyrocytes have a very limited tumorigenic capacity. The same mutations result in teratocarcinomas when delivered in early differentiating hESCs. Tissue Inhibitor of Metalloproteinase 1 (TIMP1)/Matrix metallopeptidase 9 (MMP9)/Cluster of differentiation 44 (CD44) ternary complex, in cooperation with Kisspeptin receptor (KISS1R), is involved in TC initiation and progression. Increasing radioiodine uptake, KISS1R and TIMP1 targeting may represent a therapeutic adjuvant option for undifferentiated TCs.
Keywords:
SIGNALING PATHWAYS
P53 MUTATIONS
CARCINOMAS
DIFFERENTIATION
ASSOCIATION
METASTASIS
MANAGEMENT
PAPILLARY
SURFACE
SYSTEM
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Nature Communications cover
Nature Communications
IF:
15.7
Papers:
9.2W
Citations:
91.2W

Organization

Q
Queen Mary University London
Scholars:
2.0W
Papers: 1.5W
Citations: 327
U
University of Palermo
Scholars:
1.9W
Papers: 1.5W
Citations: 1.5W
U
university of london
Scholars:
21.3W
Papers: 19.6W
Citations: 305
U
University of Catania
Scholars:
1.9W
Papers: 1.4W
Citations: 20
researcher View more organizations